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IntroductIon
The	Rh	 blood	 group	 system	 is	 one	 of	 the	most	 im-
portant,	complex	and	immunogenic	systems	known	in	
humans	because	of	its	involvement	in	the	newborn’s	
hemolytic	disease,	 the	 transfusion	 reactions,	and	 the	
autoimmune	 hemolytic	 anemia.	 D	 antigen	 is	 highly	
immunogenic	and	is	the	most	important	blood	group	
antigen	in	terms	of	clinical	significance	1,2,3.
Prior	to	the	1970s,	haemolytic	disease	of	the	fetus	
and	newborn	(HDFN)	was	a	significant	cause	of	fetal	
and	neonatal	morbidity	and	mortality.	HDFN	is	usu-
ally	caused	by	immunoglobulin	G	(IgG)	antibodies	to	
the	D	antigen	of	the	Rh	system	in	a	D-negative	(D–)	
mother	crossing	the	placenta	and	facilitating	the	im-
mune	destruction	 of	D-positive	 (D+)	 fetal	 red	 cells.	
Since	1968,	with	the	introduction	of	immune	prophy-
laxis	to	prevent	Rhesus	(Rh)D	allo-immunization,	the	
risk	 of	 anti-RhD	 allo-immunization	 has	 been	mark-
edly	reduced	(1	to	6	per	1000	live	births)	4,5.
However,	 administration	 of	 blood	 derivatives	 is	
not	devoid	of	risk,	and	every	effort	should	be	made	to	
improve	techniques	that	could	reduce	the	number	of	
injections.	Therefore,	the	new	possibility	of	fetal	RHD	
genotyping	using	polymerase	chain	reaction	(PCR)	is	
a	significant	advance	for	clinical	purpose.	Fetal	RHD	
genotype	determination	is	useful	in	the	management	
of	 RhD-negative	 sensitized	 women.	 Genotyping	 is	
also	useful	in	RhD-negative	pregnant	women	at	risk	
for	RhD	immunization	in	order	to	avoid	unnecessary	
administration	of	anti-D	immunoglobulin,	in	the	case	
of	 an	RhD-negative	 fetus6,7.	 In	 this	 study,	we	 deter-
mined	 the	accuracy	of	 the	non-invasive	prenatal	de-
termination	 of	 fetal	 RhD	 genotyping	 by	 the	 use	 of	
real-time	PCR8.
MaterIals and Methods
DNA extraction from plasma samples
Forty	eight	RhD-negative	pregnant	women	in	the	sec-
ond	and	third	trimester	and	six	positive	RhD	samples	
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as	controls	elected	to	participate	for	noninvasive	pre-
natal	determination	by	maternal	plasma	analysis.	Five	
mL	of	blood	were	collected	into	EDTA-	tubes.	Imme-
diately,	blood	samples	were	centrifuged	 for	10	min-
utes	at	3000g,	and	the	plasma	was	collected	in	fresh	
tubes	and	stored	in	-80oC	until	it	was	used	for	DNA	
isolation.	DNA	was	extracted	from	200	μl	plasma	us-
ing	QIAamp	DNA	Blood	Mini	Kit	 (Qiagen;	Hilden,	
Germany).	
Real-time PCR for the RHD gene in maternal plasma
The	 procedure	 was	 similar	 to	 that	 previously	 de-
scribed5,8-10.	Amplification	was	carried	out	in	a	Light-	
Cycler	 instrument	(Roche	Biochemicals).	PCR	reac-
tions	were	 set	 up	 in	 a	 final	 volume	 of	 20	 μL	 using	
the	FastDNAMaster	Hybridization	Probes	Kit	(Roche	
Biochemicals),	with	0.5	mmol/L	of	each	primer,	0.25	
mmol/L	of	each	probe	(Proligo,	France)	(Table),	1	unit	
of	uracil	DNA	glycosylase	 (UNG,	heat	 labile)	 (Bio-
labs,	Saint-Quentin	en	Yvelines,	France),	4.0	mmol/L	
of	magnesium	chloride.	After	an	initial	10	minutes	de-
naturation	step	at	95oC,	was	followed	by	an	amplifica-
tion	performed	for	50	cycles	of	denaturation	(95oC,	10	
seconds,	ramping	rate	20oC/sec),	annealing	(56	oC,	10	
seconds,	ramping	rate	20oC/sec),	and	extension	(72oC,	
20	seconds,	ramping	rate	20oC/sec).
Each	 sample	was	 treated	 twice	 for	DNA	 extrac-
tion.	The	results	were	compared	with	those	obtained	
after	birth,	by	RHD	serology	of	the	newborn.
results
Among	the	48	pregnant	women	tested	for	RHD	gene	
presence	 in	 their	plasma,	 the	status	of	 the	 fetus	was	
determined	in	all	48	cases.	Among	48	RhD	pregnant	
women,	9	were	in	their	second	trimester	of	pregnancy	
and	the	other	39	in	third	trimester.	In	29	cases,	RHD	
sequences	had	been	detected	in	maternal	plasma,	and	
the	fetuses	could	therefore	be	considered	as	RhD-pos-
itive,	while	 the	others	 (n	=	19)	were	RhD-	negative	
(Figure 1).	
Results	 were	 in	 complete	 concordance,	 and	 nei-
ther	false-negative	nor	false-positive	results	were	ob-
served.	The	fetal	RHD	genotype	in	all	cases	matched	
in	100%	with	the	results	obtained	from	RhD	serology	
typing	of	the	newborns.
dIscussIon
Noninvasive	 prenatal	 diagnosis	 is	 one	 of	 the	 many	
major	goals	in	human	genetics.	The	discovery	of	cell-
Figure	1�	Detection	of	the	RHD	gene	in	maternal	plasma	using	real-time	PCR.	Typical	results	observed	from	samples:	line	
1	is	a	positive	RHD	sample	(positive	control),	lines	2-5	are	fetal	DNA	positive	RHD	samples	and	lines	6-8	are	fetal	DNA	
negative	samples.
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free	fetal	DNA	in	maternal	plasma	in	1997	has	opened	
up	new	possibilities	for	noninvasive	prenatal	diagno-
sis.	Circulating	fetal	DNA	has	been	shown	to	increase	
in	concentrations	with	the	progress	in	gestational	age	
and	 to	 be	 cleared	 rapidly	 following	 delivery.	 With	
the	use	of	real-time	polymerase	chain	reaction	(PCR)	
methodology,	circulating	fetal	DNA	has	been	detect-
ed	 robustly	 in	 the	plasma	of	 pregnant	women,	 even	
early	 in	 the	first	 trimester	 of	 pregnancy.	As	 a	 result	
of	these	developments,	fetal	DNA	in	maternal	plasma	
has	been	used	for	the	noninvasive	prenatal	diagnosis	
of	sex-linked	disorders	and	single	gene	disorders	such	
as	 beta-thalassemia,	 congenital	 adrenal	 hyperplasia	
and	achondroplasia.	 In	addition,	quantitative	aberra-
tions	of	circulating	fetal	DNA	have	been	also	found	
in	various	pregnancy-associated	disorders,	 including	
preeclampsia,	preterm	labor	and	fetal	trisomy11-14.
One	of	the	first	clinical	applications	of	noninvasive	
detection	of	fetal	DNA	in	the	mother	was	for	rhesus	
D	typing	of	the	fetus.	Fetal	RHD	genotype	can	be	de-
termined	with	a	high	level	of	accuracy	by	analysis	of	
fetal	DNA	circulating	in	maternal	plasma	and	serum.	
It	is	therefore	possible	to	consider	that	such	an	assay	
could	 be	 included	 in	 prenatal	 care	 of	RhD-negative	
women15,16.
We	performed	fetal	RHD	genotyping	using	mater-
nal	plasma	from	48	pregnant	women	in	16-40	weeks	
of	 pregnancy.	 Serological	 RhD	 typing	 of	 the	 new-
borns	 showed	 100%	 concordance	 between	 genomic	
and	 serological	 typing.	Among	 the women studied,	 	 	
39.6%	carried	an RhD-negative fetus. In these cases,	 	 	 	 	 	
no	prenatal	anti-D	prophylaxis	is	needed	and	injection	
of	anti-D	immunoglobulin can be avoided. Follow-up	 	 	 	 	
of	pregnancy	is	therefore	made	easier,	decreasing	the	
patient’s	anxiety.
Traditional	 management	 for	 RhD-negative	 preg-
nant	 women	 at	 risk	 for	 RHD	 alloimmunization	 in-
volves	determining	the	RhD	status	of	the	fetus	through	
invasive	chorionic	villus	 sampling	 (CVS)	or	 amnio-
centesis,	 and	 administrating	 the	 prophylactic	 human	
derived	Rho(D)	Immune	Globulin	during	pregnancy	
and	after	delivery.	Both	practices	carry	their	own	risks	
and	 associated	 costs17.	 In	many	European	 countries,	
studies	showed	that	fetal	RHD	genotyping	from	ma-
ternal	plasma	can	save	up	to	40	percent	of	the	prenatal	
anti-D	injections,	because	treatment	is	only	limited	in	
women	with	RhD-positive	fetuses18.
Hence,	the	ability	to	determine	this	important	fe-
tal	DNA	RHD	locus	in	maternal	plasma,	in	a	non-in-
vasive	manner	 using	 real-time	 PCR,	 presents	 a	 sig-
nificant	achievement	in	the	application	of	research	to	
clinical	routine19.
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reFerences
ΠΕΡΙΛΗΨΗ:	Εισαγωγή και Σκοπός:	Ο	καθορισμός	της	εμβρυϊκής	RHD	τυποποίησης	χρησιμοποιώντας	ελεύθερο	εμβρυϊκού	
DNA	από	μητρικό	πλάσμα	έχει	αρχίσει	να	κερδίζει	ευρεία	αποδοχή	στην	Ευρώπη	και	είναι	δυνατόν	να	επιτρέψει	τη	γενετική	
ανάλυση	χωρίς	τη	χρήση	παρεμβατικών	μεθόδων.	Ο	σκοπός	της	συγκεκριμένης	εργασίας	ήταν	η	απομόνωση	εμβρυϊκού	
DNA	από	μητρικό	πλάσμα	και	ο	καθορισμός	της	ακρίβειας	μιας	μη	παρεμβατικής	προγεννητικής	διάγνωσης	του	εμβρυϊκού	
RHD	γονότυπου	με	τη	χρήση	της	real-time	PCR.
Υλικό και Μέθοδος:	Μελετήθηκαν	48	RhD	αρνητικές	έγκυες	γυναίκες	μεταξύ	16ης	και	40ης	εβδομάδας	κύησης	με	τη	μέθοδο	
real-time	PCR	και	τη	χρησιμοποίηση	αφετηριών	και	ανιχνευτών	κατάλληλων	για	το	RHD	γονίδιο.	Τα	αποτελέσματα	συ-
γκρίθηκαν	με	ορολογική	RhD	τυποποίηση	των	νεογνών.
Αποτελέσματα:	Από	τις	48	RhD	αρνητικές	έγκυες	γυναίκες,	9	ήταν	στο	δεύτερο	τρίμηνο	της	κύησης	και	οι	39	στο	τρίτο	
τρίμηνο.	Είκοσι	εννέα	έμβρυα	τυποποιήθηκαν	ως	RhD	θετικά	και	19	RhD	αρνητικά.	Δεν	παρατηρήθηκαν	ψευδώς	αρνητικά	
ούτε	ψευδώς	θετικά	αποτελέσματα.
Συμπέρασμα:	Με	την	παρούσα	εργασία	γίνεται	φανερό	ότι	ο	αξιόπιστος	RHD	γονοτυπικός	καθορισμός	μπορεί	να	επιτευχθεί	
με	100%	ακρίβεια.	Παρόμοιες	μελέτες	είναι	επομένως	δυνατόν	να	εφαρμοστούν	συστηματικά	σε	όλες	τις	RHD	αρνητικές	
έγκυες	γυναίκες	με	απώτερο	σκοπό	την	αποτελεσματικότερη	RhD	προφύλαξη.
Λέξεις Κλειδιά: Εμβρυϊκό DNA, Μητρικό πλάσμα, R�D γονότυπος.
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